fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

European Commission approval for Cosentyx as first and only IL-17A inhibitor for hidradenitis suppurativa – Novartis

Written by | 14 Jun 2023

Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to… read more.

Kisqali significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent .across subgroups – Novartis

Written by | 10 Jun 2023

Novartis presents positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting . Data showed that… read more.

NICE (UK) recommends Adakveo as a treatment for preventing recurrent sickle cell crises – Novartis

Written by | 29 Oct 2021

Novartis is pleased to announce that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA). The news… read more.

Rydapt receives NICE recomendation to treat agressive systemic mastocytosis – Novartis

Written by | 30 Aug 2021

Novartis welcomed the news that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending Rydapt (midostaurin) for the treatment of aggressive… read more.

Entresto approved in China to treat essential hypertension – Novartis

Written by | 24 Jun 2021

Novartis announced that Entresto (sacubitril/valsartan) has received a new indication in China for the treatment of patients with essential hypertension, a disease affecting approximately 245 million adults in… read more.

FDA approves Xolair prefilled syringe for self-injection across all indications – Genentech + Novartis

Written by | 24 Apr 2021

Genentech, a member of the Roche Group announced that the FDA has approved the company’s supplemental Biologics License Application for Xolair (omalizumab) prefilled syringe for self-injection across all… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.